Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 250

1.

Matrix metalloproteinase inhibitors and cancer: trials and tribulations.

Coussens LM, Fingleton B, Matrisian LM.

Science. 2002 Mar 29;295(5564):2387-92. Review.

PMID:
11923519
2.

Matrix metalloproteinase inhibitors as anticancer therapeutics.

Mannello F, Tonti G, Papa S.

Curr Cancer Drug Targets. 2005 Jun;5(4):285-98. Review.

PMID:
15975049
3.

Matrix metalloproteinase inhibitors.

Ramnath N, Creaven PJ.

Curr Oncol Rep. 2004 Mar;6(2):96-102. Review.

PMID:
14751086
4.

Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment.

Zucker S, Cao J, Chen WT.

Oncogene. 2000 Dec 27;19(56):6642-50. Review.

5.

Natural bio-drugs as matrix metalloproteinase inhibitors: new perspectives on the horizon?

Mannello F.

Recent Pat Anticancer Drug Discov. 2006 Jan;1(1):91-103. Review.

PMID:
18221029
6.

Progress in the development of matrix metalloproteinase inhibitors.

Tu G, Xu W, Huang H, Li S.

Curr Med Chem. 2008;15(14):1388-95. Review.

PMID:
18537616
7.

Development of matrix metalloproteinase inhibitors in cancer therapy.

Hidalgo M, Eckhardt SG.

J Natl Cancer Inst. 2001 Feb 7;93(3):178-93. Review.

PMID:
11158186
8.

Matrix metalloproteinase inhibitors: do they have a place in anticancer therapy?

Rudek MA, Venitz J, Figg WD.

Pharmacotherapy. 2002 Jun;22(6):705-20. Review.

PMID:
12066962
9.

Matrix metalloproteinase inhibitors for cancer therapy:the current situation and future prospects.

Fingleton B.

Expert Opin Ther Targets. 2003 Jun;7(3):385-97. Review.

PMID:
12783574
10.

[Expression of matrix metalloproteinases in patients with malignant tumors].

Stanciūte D, Didziapetriene J, Kadziauskas J.

Medicina (Kaunas). 2004;40(12):1143-50. Review. Lithuanian.

11.

[Metalloproteinases in tumor progression. Review].

Arvelo F, Cotte C.

Invest Clin. 2006 Jun;47(2):185-205. Review. Spanish.

PMID:
16886780
12.

Matrix metalloproteinases. Novel targets for directed cancer therapy.

Yu AE, Hewitt RE, Connor EW, Stetler-Stevenson WG.

Drugs Aging. 1997 Sep;11(3):229-44. Review.

PMID:
9303281
13.

Matrix metalloproteinase inhibitors: current developments and future perspectives.

Hoekstra R, Eskens FA, Verweij J.

Oncologist. 2001;6(5):415-27. Review.

14.

Induction of tumour cell apoptosis by matrix metalloproteinase inhibitors: new tricks from a (not so) old drug.

Mitsiades N, Poulaki V, Mitsiades CS, Anderson KC.

Expert Opin Investig Drugs. 2001 Jun;10(6):1075-84. Review.

PMID:
11772236
15.

Development of matrix metalloproteinase inhibitors in cancer therapy.

Purcell WT, Rudek MA, Hidalgo M.

Hematol Oncol Clin North Am. 2002 Oct;16(5):1189-227. Review.

PMID:
12512389
17.

Matrix metalloproteinases as therapeutic targets in cancer.

Vihinen P, Ala-aho R, Kähäri VM.

Curr Cancer Drug Targets. 2005 May;5(3):203-20. Review.

PMID:
15892620
18.

Matrix metalloproteinases in tumorigenesis: an evolving paradigm.

Hua H, Li M, Luo T, Yin Y, Jiang Y.

Cell Mol Life Sci. 2011 Dec;68(23):3853-68. doi: 10.1007/s00018-011-0763-x. Epub 2011 Jul 10. Review.

PMID:
21744247
19.

Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies.

Folgueras AR, Pendás AM, Sánchez LM, López-Otín C.

Int J Dev Biol. 2004;48(5-6):411-24. Review.

20.

Anti-invasive, antitumoral, and antiangiogenic efficacy of a pyrimidine-2,4,6-trione derivative, an orally active and selective matrix metalloproteinases inhibitor.

Maquoi E, Sounni NE, Devy L, Olivier F, Frankenne F, Krell HW, Grams F, Foidart JM, Noël A.

Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4038-47.

Supplemental Content

Support Center